| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-519 | |
| Phytochemical name or plant extracts | Tonkinensine B | |
| PMID | 34313786 | |
| Literature evidence | OBJECTIVES: Tonkinensine B, a novel compound with cytisine-pterocarpan skeleton isolated from the root of Sophora tonkinensis Gagnep, was reported to have a significant antitumor effect. | |
| IUPAC name | (1R,9S)-11-[[(1R,12R)-16-hydroxy-5,7,11,19-tetraoxapentacyclo[10.8.0.02,10.04,8.013,18]icosa-2,4(8),9,13(18),14,16-hexaen-17-yl]methyl]-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one | |
| Phytochemicals’ class or type of plant extracts | Alkaloid | |
| Source of phytochemicals or plant Extracts | Sophora tonkinensis | |
| Geographical availability | China South-Central, China Southeast, Vietnam | |
| Plant parts | Root | |
| Other cancers | Breast cancer | |
| Target gene or protein | Bax, Bcl-2, Caspase 3, Caspase 9 | |
| Gene or Protein evidence | Furthermore, the proportions of Bax/Bcl-2, cleaved caspase-3 and caspase-9 proteins production were up-regulated, indicating that tonkinensine B acted on intrinsic mitochondrial-mediated apoptosis pathway. | |
| Target pathways | PI3K/AKT pathway | |
| IC50 | 71.2 ± 6.5 μM against MDA-MB-231 56 ± 4.4 μM against 4T1 | |
| Potency | Tonkinensine B may be a hopeful candidate for human triple-negative breast cancer, and further structural optimization is expected to improve its anti-tumour activity. | |
| Cell line/ mice model | MDA-MB-231, 4T1 | |
| Additional information | In addition, tonkinensine B also reduced phosphorylation levels of AKT, and thus the activation of apoptosis might likewise be correlated with the inhibition of the PI3K/AKT pathway. | |
| PubChem ID | 24898926 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:518956-1 | |
| Safety | NA |